vs
先锋自然资源公司（PR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
先锋自然资源公司的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），先锋自然资源公司净利率更高（29.0% vs 12.7%，领先16.3%），Revvity同比增速更快（5.9% vs -9.8%），过去两年Revvity的营收复合增速更高（9.0% vs -3.0%）
先锋自然资源公司总部位于美国得克萨斯州欧文市，主要从事油气勘探业务，运营覆盖二叠纪盆地Spraberry产区的克莱恩页岩区块，是该区域最大的土地权益持有方，2024年5月被埃克森美孚收购。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PR vs RVTY — 直观对比
营收规模更大
PR
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出15.6%
-9.8%
净利率更高
PR
高出16.3%
12.7%
两年增速更快
RVTY
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $339.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 23.1% | 14.5% |
| 净利率 | 29.0% | 12.7% |
| 营收同比 | -9.8% | 5.9% |
| 净利润同比 | 56.7% | 3.9% |
| 每股收益（稀释后） | $0.48 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润PRRVTY
| Q4 25 | $339.5M | $98.4M | ||
| Q3 25 | $59.2M | $46.7M | ||
| Q2 25 | $207.1M | $53.9M | ||
| Q1 25 | $329.3M | $42.2M | ||
| Q4 24 | $216.7M | $94.6M | ||
| Q3 24 | $386.4M | $94.4M | ||
| Q2 24 | $235.1M | $55.4M | ||
| Q1 24 | $146.6M | $26.0M |
毛利率PRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PRRVTY
| Q4 25 | 23.1% | 14.5% | ||
| Q3 25 | 29.6% | 11.7% | ||
| Q2 25 | 24.8% | 12.6% | ||
| Q1 25 | 36.6% | 10.9% | ||
| Q4 24 | 32.8% | 16.3% | ||
| Q3 24 | 32.5% | 14.3% | ||
| Q2 24 | 36.5% | 12.4% | ||
| Q1 24 | 37.7% | 6.8% |
净利率PRRVTY
| Q4 25 | 29.0% | 12.7% | ||
| Q3 25 | 4.5% | 6.7% | ||
| Q2 25 | 17.3% | 7.5% | ||
| Q1 25 | 23.9% | 6.4% | ||
| Q4 24 | 16.7% | 13.0% | ||
| Q3 24 | 31.8% | 13.8% | ||
| Q2 24 | 18.9% | 8.0% | ||
| Q1 24 | 11.8% | 4.0% |
每股收益（稀释后）PRRVTY
| Q4 25 | $0.48 | $0.86 | ||
| Q3 25 | $0.08 | $0.40 | ||
| Q2 25 | $0.28 | $0.46 | ||
| Q1 25 | $0.44 | $0.35 | ||
| Q4 24 | $0.31 | $0.77 | ||
| Q3 24 | $0.53 | $0.77 | ||
| Q2 24 | $0.36 | $0.45 | ||
| Q1 24 | $0.25 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $153.7M | $919.9M |
| 总债务越低越好 | $3.5B | — |
| 股东权益账面价值 | $10.3B | $7.3B |
| 总资产 | $17.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资PRRVTY
| Q4 25 | $153.7M | $919.9M | ||
| Q3 25 | $111.8M | $931.4M | ||
| Q2 25 | $451.0M | $991.8M | ||
| Q1 25 | $702.2M | $1.1B | ||
| Q4 24 | $479.3M | $1.2B | ||
| Q3 24 | $272.0M | $1.2B | ||
| Q2 24 | $47.8M | $2.0B | ||
| Q1 24 | $12.7M | $1.7B |
总债务PRRVTY
| Q4 25 | $3.5B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.0B | — | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $3.9B | — | ||
| Q1 24 | $3.9B | — |
股东权益PRRVTY
| Q4 25 | $10.3B | $7.3B | ||
| Q3 25 | $10.0B | $7.4B | ||
| Q2 25 | $9.5B | $7.6B | ||
| Q1 25 | $9.4B | $7.6B | ||
| Q4 24 | $9.1B | $7.7B | ||
| Q3 24 | $9.0B | $7.9B | ||
| Q2 24 | $8.3B | $7.9B | ||
| Q1 24 | $7.0B | $7.8B |
总资产PRRVTY
| Q4 25 | $17.9B | $12.2B | ||
| Q3 25 | $17.3B | $12.1B | ||
| Q2 25 | $17.5B | $12.4B | ||
| Q1 25 | $17.1B | $12.4B | ||
| Q4 24 | $16.9B | $12.4B | ||
| Q3 24 | $16.6B | $12.8B | ||
| Q2 24 | $15.4B | $13.4B | ||
| Q1 24 | $15.1B | $13.4B |
负债/权益比PRRVTY
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.46× | — | ||
| Q1 24 | 0.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $904.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 2.66× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PRRVTY
| Q4 25 | $904.3M | $182.0M | ||
| Q3 25 | $766.5M | $138.5M | ||
| Q2 25 | $1.0B | $134.3M | ||
| Q1 25 | $898.0M | $128.2M | ||
| Q4 24 | $871.6M | $174.2M | ||
| Q3 24 | $954.4M | $147.9M | ||
| Q2 24 | $938.4M | $158.6M | ||
| Q1 24 | $647.6M | $147.6M |
自由现金流PRRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率PRRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度PRRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率PRRVTY
| Q4 25 | 2.66× | 1.85× | ||
| Q3 25 | 12.94× | 2.97× | ||
| Q2 25 | 5.01× | 2.49× | ||
| Q1 25 | 2.73× | 3.03× | ||
| Q4 24 | 4.02× | 1.84× | ||
| Q3 24 | 2.47× | 1.57× | ||
| Q2 24 | 3.99× | 2.87× | ||
| Q1 24 | 4.42× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PR
| Crude Oil | $1.0B | 87% |
| Natural Gas Liquids Reserves | $145.1M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
